Breaking News

Merck to buy Terns Pharmaceuticals in $6.7B deal 

March 25, 2026
Pharmalot Columnist, Senior Writer
Adobe

STAT+ | Merck to buy Terns Pharmaceuticals in $6.7B deal

The deal's centerpiece is a promising leukemia drug, which could help Merck offset the impending decline of Keytruda revenue.

By Adam Feuerstein


STAT+ | How an outsider crept into Eli Lilly's top ranks — and plans to drive its business forward 

Lilly acquired both drug rights and top talent in the $8 billion deal. Here's an inside look at how Loxo's Jacob Van Naarden rose to power inside Eli Lilly.

By Matthew Herper


STAT+ | FDA approves Denali Therapeutics drug for Hunter syndrome

The decision is notable in part because it follows a string of FDA rejections or calls for additional data on rare disease drugs.

By Andrew Joseph and Jason Mast



Charles Krupa/AP

STAT+ | Sarepta Therapeutics shares rise on early promise for rare disease drugs

New results from small studies in a pair of treatments for rare, muscle-wasting diseases could support the beleaguered company's pivot.

By Damian Garde


Opinion: We're launching a new CMS pilot program to help children with complex conditions

The new CMS pilot project ASPIRE aims to connect physical health, behavioral health, and community support to help kids and parents.

By Mehmet Oz and Abe Sutton


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments